Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 3:10 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Cormorant Asset Management LP | 8,325,000 12.200% | 2,286,765 (+37.87%) | View |
| 2024-11-14 1:22 pm Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | PRICE T ROWE ASSOCIATES INC | 2,492,213 4.700% | -30,491 (-1.21%) | View |
| 2024-11-12 2:31 pm Unchanged | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | VANGUARD GROUP INC | 3,048,182 5.690% | 0 (Unchanged) | View |
| 2024-11-12 09:33 am Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Adage Capital Management L.P. | 3,791,420 7.080% | -1,364,879 (-26.47%) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | BlackRock Inc. | 4,155,158 7.800% | 0 (Unchanged) | View |
| 2024-11-07 4:27 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | TCG Crossover GP II LLC | 3,572,335 5.200% | 3,572,335 (New Position) | View |
| 2024-11-06 08:54 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FEDERATED HERMES INC. FHI | 3,707,364 5.440% | 3,707,364 (New Position) | View |
| 2024-11-04 11:57 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | VANGUARD GROUP INC | 3,048,182 5.690% | 3,048,182 (New Position) | View |
| 2024-10-22 3:24 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | BlackRock Inc. | 4,155,158 7.800% | 4,155,158 (New Position) | View |
| 2024-05-01 5:08 pm Unchanged | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Adage Capital Management L.P. | 5,156,299 9.900% | 0 (Unchanged) | View |
| 2024-04-30 8:53 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Adage Capital Management L.P. | 5,156,299 10.350% | 5,156,299 (New Position) | View |
| 2024-02-14 9:08 pm Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | RA CAPITAL MANAGEMENT L.P. | 3,095,136 6.100% | -313,570 (-9.20%) | View |
| 2024-02-14 10:02 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | PRICE T ROWE ASSOCIATES INC | 2,522,704 5.600% | 2,522,704 (New Position) | View |
| 2024-02-13 12:00 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 4,774,389 9.990% | 1,363,179 (+39.96%) | View |
| 2024-02-07 07:54 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,466,420 9.150% | 2,516,420 (+129.05%) | View |
| 2024-02-06 10:55 am Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 4,640,651 9.500% | 510,514 (+12.36%) | View |
| 2023-12-14 4:04 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | Cormorant Asset Management LP | 6,038,235 12.360% | 6,038,235 (New Position) | View |
| 2023-12-08 5:28 pm Sale | 13D | EYEPOINT PHARMACEUTICALS, INC. EYPT | EW Healthcare Partners L.P. | 2,337,786 5.000% | -1,312,606 (-35.96%) | View |
| 2023-09-11 11:15 am Sale | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | FRANKLIN RESOURCES INC BEN | 4,130,137 11.800% | -1,644,372 (-28.48%) | View |
| 2023-08-30 5:22 pm Sale | 13D | EYEPOINT PHARMACEUTICALS, INC. EYPT | EW Healthcare Partners L.P. | 3,650,392 10.400% | -38,253,564 (-91.29%) | View |